Table 3.

IC50 value for 5-FU after treatment with the PPARG agonists pioglitazone, rosiglitazone and the PPARG inhibitor GW9662

	Treatment	IC50 (μM) average + standard deviation	p-value paired t-test	p-value Wilcoxon-Rank test
HT29	Control	31.4 ± 8.2
	Pio 80 μM	4.4 ± 0.8	< 0.0001	< 0.01
	Rosi 80 μM	5.3 ± 0.7	< 0.0001	< 0.01
	GW9662 10 μM	100.5 ± 69.9	0.03	< 0.01
SW403	Control	10.6 ± 1.9
	Pio 80 μM	3.8 ± 0.6	< 0.0001	< 0.01
	Rosi 80 μM	5.0 ± 1.7	< 0.001	< 0.01
	GW9662 10 μM	18.8 ± 16.1	0.19	0.426